Andrew Makin Preclinical Consulting ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 5.9% 5.1% 3.3% 3.4%  
Credit score (0-100)  0 39 42 54 53  
Credit rating  N/A BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 848 1,516 1,561 1,353  
EBITDA  0.0 324 593 556 581  
EBIT  0.0 324 593 556 581  
Pre-tax profit (PTP)  0.0 324.4 586.1 549.0 575.7  
Net earnings  0.0 252.4 456.4 427.7 449.0  
Pre-tax profit without non-rec. items  0.0 324 586 549 576  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 292 549 668 690  
Interest-bearing liabilities  0.0 0.0 4.3 0.0 0.0  
Balance sheet total (assets)  0.0 637 858 1,011 1,142  

Net Debt  0.0 -536 -556 -737 -725  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 848 1,516 1,561 1,353  
Gross profit growth  0.0% 0.0% 78.7% 3.0% -13.3%  
Employees  0 0 0 2 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 637 858 1,011 1,142  
Balance sheet change%  0.0% 0.0% 34.6% 17.9% 12.9%  
Added value  0.0 324.5 593.0 555.9 580.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 2.0 3.0 4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 38.2% 39.1% 35.6% 42.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 51.0% 79.3% 59.5% 54.1%  
ROI %  0.0% 111.2% 140.3% 91.0% 85.7%  
ROE %  0.0% 86.3% 108.5% 70.3% 66.1%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 45.9% 64.0% 66.1% 60.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -165.3% -93.8% -132.5% -124.8%  
Gearing %  0.0% 0.0% 0.8% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 322.0% 319.7% 0.0%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 1.8 2.8 3.0 2.5  
Current Ratio  0.0 1.8 2.8 3.0 2.5  
Cash and cash equivalent  0.0 536.2 560.5 736.7 724.5  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 292.4 548.8 668.5 689.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 278 290  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 278 290  
EBIT / employee  0 0 0 278 290  
Net earnings / employee  0 0 0 214 225